Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Insmed Inc
INSM
Healthcare
Biotechnology
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination...
antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung diseas...
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (NDAQ:INSM)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(0)
•••
mornings1
X
Comment by
mornings1
on Jun 23, 2009 3:14pm
RE: Upcoming FDA decision on the approval of a sma
That's nice, but you're not talking about INSM. It's is scheduled for 06/26.Please stop spamming for a not free financial rag
(0)
•••
sebaxter
X
Post by
sebaxter
on Mar 27, 2008 1:14pm
NEWS RELEASE
Momenta, Insmed May Gain From Biotech Generics Law (Update1) By Catherine Larkin March 27 (Bloomberg) -- Momenta Pharmaceuticals Inc., Insmed Inc. and Cell Therapeutics Inc. are poised to
...more
(7)
•••
scissors14
X
Post by
scissors14
on Apr 30, 2007 4:27pm
Investor Fact Sheet with Updates
Insmed Inc. Releases Investor Fact Sheet with Updates on Drug Development Progress RICHMOND, Va., Apr 25, 2007 (BUSINESS WIRE) -- Insmed Inc. (NASDAQ:INSM), a biopharmaceutical company engaged
...more
(0)
•••
jamieb3
X
Post by
jamieb3
on Dec 26, 2006 4:33pm
down to 80 cents this AM
I keep looking at this stock. It was down as low as 80 cents and closed at 87. They lost the infringment case to TRCA and DNA, but have European approval. Hard to say what is going to happen. They
...more
(7)
•••
scissors14
X
Post by
scissors14
on Sep 04, 2006 11:08pm
Impressive Launch....C.E.Unterberg, Towbin
Impressive Launch....C.E.Unterberg, Towbin Insmed, Inc. (INSM5,6,7,8,9 $1.18) Buy 2Q:06 Results - Impressive Launch "We believe 2Q:06 results are an early indication of the drugs
...more
(7)
•••
scissors14
X
Post by
scissors14
on Jun 13, 2006 8:53am
Insmed Wins Court Case
Court Dismisses Baseless Unfair Business Practices Lawsuit That Was Brought Against Insmed RICHMOND, Va., Jun 13, 2006 (BUSINESS WIRE) -- Insmed Incorporated (Nasdaq:INSM): On June 9, 2006, the
...more
(7)
•••
scissors14
X
Post by
scissors14
on May 25, 2006 8:36am
IPLEX(TM) Availability Nationwide
INSMED Announces IPLEX(TM) Availability Nationwide for Children with Severe Short Stature; IPLEX Launch Marked By The First Product Shipments To Patients in States Across the Country
...more
(7)
•••
scissors14
X
Post by
scissors14
on May 20, 2006 11:09pm
Great Post On Yahoo...
I think this post just about captures it all, it's a great price right here IMO... https://messages.yahoo.com/bbs?action=m&board=1600811390&tid=insm&sid=1600811390&mid=98134
...more
(7)
•••
scissors14
X
Post by
scissors14
on Apr 23, 2006 9:20pm
Completes $46 Million Public Offering
Insmed Completes $46 Million Public Offering; Underwriters Exercise In Full Option to Purchase Additional Shares RICHMOND, Va., Mar 15, 2006 (BUSINESS WIRE) -- Insmed Incorporated (NASDAQ:INSM
...more
(0)
•••
dealorfx
X
Post by
dealorfx
on Mar 08, 2006 8:05pm
loading up here at these levels,
will hold for 6 to 12 months, .....$$$
(7)
•••
scissors14
X
Post by
scissors14
on Jan 04, 2006 11:57am
U. of Rochester Phase 2 Clinical Trial
U. of Rochester Initiates Phase 2 Clinical Trial of Insmed's iPlex for the Treatment of Myotonic Muscular Dystrophy; Trial Funded by NIH and MDA Grants RICHMOND, Va. & ROCHESTER, N.Y. &
...more
(7)
•••
scissors14
X
Post by
scissors14
on Dec 13, 2005 2:17pm
FDA Approves Insmed's Orphan Drug IPLEX
FDA Approves Insmed's Orphan Drug, IPLEX, for the Treatment of Severe Primary IGF-1 Deficiency; The First Once-Daily Therapy for the Treatment of Severe Primary IFG-1 Deficiency 12/12/05
...more
(0)
•••
queue
X
Comment by
queue
on Oct 18, 2005 7:09pm
Tobin Smith
Total loser. Dwells on his one hit wonders and purchases in obvious markets that don't fit his Changewave methodology. Cheesey newsletter writer. Still hyping the Wimax play. It isn't
...more
(0)
•••
longshot7
X
Comment by
longshot7
on Sep 28, 2005 12:58pm
News
Insmed Receives Approvable Letter for iPlex(TM); Conference Call Tomorrow at 8:00am EST Lookin' good! PS. Hey scissors14, stop double clicking on the "post" button
(7)
•••
scissors14
X
Comment by
scissors14
on Aug 31, 2005 8:29pm
FDA Approves Tercica's Increlex
FDA Approves Tercica's Increlex Matthew Herper, 08.31.05, 9:00 AM ET The Food and Drug Administration has approved Increlex, a medicine developed by biotech Tercica (nasdaq: TRCA - news
...more
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Sranan Gold Reports 11 M Grading 7.33 g/t Gold Including 4 M at 14.59 g/t Gold
Global Currency Shifts Are Reshaping Commodities. Learn How. Secure Your Seat at VRIC 2026
Pinnacle Provides Progress Update for El Potrero Gold-Silver Project
Allied Critical Metals Announces Receipt of Environmental Permit for the Borralha Tungsten Project in Portugal
Team Spotlight: Every discovery begins with the people behind it
Podcasts